A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome

Blood

Volumn 104, Issue 2, 2004, Pages 579-585

  Cutler, Corey S ^b   Lee, Stephanie J ^b   Greenberg, Peter ^b   Deeg, H Joachim ^b   Párez, Waleska S ^b   Anasetti, Claudio ^b   Bolwell, Brian J ^b   Cairo, Mitchell S ^b   Gale, Robert Peter ^b   Klein, John P ^b   Lazarus, Hillard M ^b   Liesveld, Jane L ^b   McCarthy, Philip L ^b   Milone, Gustavo A ^b   Rizzo, J Douglas ^b   Schultz, Kirk R ^b   Trigg, Michael E ^b   Keating, Armand ^b   Weisdorf, Daniel J ^b   Antin, Joseph H ^b   Horowitz, Mary M ^a   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DISEASE COURSE; HIGH RISK POPULATION; HLA MATCHING; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKEMIA; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; META ANALYSIS; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL MODEL; SURVIVAL; SYSTEMATIC REVIEW;

EID: 3142580475     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0338     Document Type: Article

References (41)

1. Anderson JE. Allogeneic hematopoietic cell transplantation for myelodysplastic and myeloproliferative disorders. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science; 1999:872-886.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
3. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndrome: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6:52-59.
4. Coiffier B, Adeleine P, Gentilhomme O, Felman P, Treille-Ritouet D, Bryon P-A. Myelodysplastic syndromes: a multiparametric study of prognostic factors in 336 patients. Cancer. 1987;60:3029-3032.
5. Cunningham I, MacCallum SJ, Nicholls MD, et al. The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol. 1995;90:602-606.
6. Maschek H, Gutzmer R, Choritz H, Georgii A. Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients. Eur J Haematol. 1994;53:280-287.
7. Morel P, Hebbar M, Lai J-L, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia. 1993;7:1315-1323.
8. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol. 1985;59:425-433.
9. Sanz GF, Sanz MA, Vallespí T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74:395-408.
10. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82:677-681.
11. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 1996;87:51-58.
12. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide and total-body irradiation and analysis of prognostic factors. J Clin Oncol. 1996;14:220-226.
13. De Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110:620-630.
14. Deeg HJ, Appelbaum FR. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Leuk Res. 2000;24:653-663.
15. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Blood. 1996;88:358-365.
16. Runde V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Bone Marrow Transplant. 1998;21:255-261.
17. Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 1998;92:1910-1917.
18. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia. 1998;12(suppl 1):S25-S29.
19. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100:1201-1207.
20. Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical Decision Analysis. Philadelphia, PA: W.B. Saunders; 1980.
21. Djulbegovic B, Hollenberg J, Woodcock TM, Herzig R. Comparison of different treatment strategies for diffuse large-cell lymphomas: a decision analysis. Med Decis Making. 1991;11:1-8.
22. Djulbegovic B, Hendler FJ, Hamm J, Hadley T, Woodcock TM. Residual mediastinal mass after treatment of Hodgkin's disease: a decision analysis. Med Hypotheses. 1992;38:166-175.
23. Lee SJ, Kuntz KM, Horowitz MM, et al. A decision analysis of unrelated donor bone marrow transplantation for chronic myelogenous leukemia. Ann Int Med. 1997;127:1080-1088.
24. Ng AK, Weeks JC, Mauch PM, Kuntz KM. Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease. J Clin Oncol. 1999;17:3577-3585.
25. Ng AK, Weeks JC, Mauch PM, Kuntz KM. Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: a decision analysis. J Clin Oncol. 1999;17:241-252.
26. Nietert PJ, Abboud MR, Silverstein MD, Jackson SM. Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis. Blood. 2000;95:3057-3064.
27. Sung L, Buckstein R, Doyle JJ, Crump M, Detsky AS. Treatment options for patients with acute myeloid leukemia with a matched sibling donor: a decision analysis. Cancer. 2003;97:592-600.
28. Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997-2004.
29. Bush NE, Donaldson GW, Haberman MH, Dacanay R, Sullivan KM. Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients. Biol Blood Marrow Transplant. 2000;6:576-591.
30. Chiodi S, Spinelli S, Ravera G, et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol. 2000;110:614-619.
31. Lee SJ, Zahrieh D, Alyea EP, et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood. 2002;100:2697-2702.
32. Worel N, Biener D, Kalhs P, et al. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant. 2002;30:619-626.
33. Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2003;121:270-274.
34. Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441-2452.
35. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440.
36. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17;3835-3849.
37. Nosslinger T, Reisner R, Koller E, et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood. 2001;98:2935-2941.
38. Greenberg P, Anderson J, De Witte T, et al. Problematic WHO re-classification of myelodysplastic syndromes. J Clin Oncol. 2000;18:3447-3449.
39. Guardiola P, Runde V, Bacigalupo A, et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood. 2002;99:4370-4378.
40. Parker JE, Shafi T, Pagliuca A, et al. Allogenetic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol. 2002;119:144-154.
41. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 2002;99:1943-1951.